1. Home
  2. BAK vs OCS Comparison

BAK vs OCS Comparison

Compare BAK & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Braskem SA ADR

BAK

Braskem SA ADR

HOLD

Current Price

$4.92

Market Cap

1.4B

Sector

Industrials

ML Signal

HOLD

Logo Oculis Holding AG Ordinary shares

OCS

Oculis Holding AG Ordinary shares

HOLD

Current Price

$27.73

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAK
OCS
Founded
1972
2003
Country
Brazil
Switzerland
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
BAK
OCS
Price
$4.92
$27.73
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$4.40
$40.43
AVG Volume (30 Days)
1.8M
298.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$418.43
Revenue Next Year
$6.45
$892.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$14.00
52 Week High
$4.30
$30.68

Technical Indicators

Market Signals
Indicator
BAK
OCS
Relative Strength Index (RSI) 72.14 48.93
Support Level $3.35 $19.00
Resistance Level N/A $29.23
Average True Range (ATR) 0.24 0.99
MACD 0.05 -0.38
Stochastic Oscillator 92.48 20.42

Price Performance

Historical Comparison
BAK
OCS

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

About OCS Oculis Holding AG Ordinary shares

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Share on Social Networks: